Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Goldman Sachs Raises USD/JPY Forecast, Sees Yen Weakness Persist Through 2027 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
Goldman Sachs Says China Competition Weighs More on EU Growth Than Trade Deficit 
JPMorgan has reinstated coverage and price targets on 14 major biotechnology companies, signaling renewed confidence in the biotech sector as firms transform successful drug pipelines into profitable commercial businesses. According to analysts led by Jessica Fye, the industry is approaching a major “inflection point,” driven by improving profitability, expanding product portfolios, and upcoming clinical catalysts.
The investment bank highlighted several biotech companies that have already reached sustained profitability, including Alnylam Pharmaceuticals, BeOne Medicines, and Ascendis Pharma. Meanwhile, Insmed and Ionis Pharmaceuticals are expected to achieve profitability soon, creating opportunities for stronger margins and long-term revenue growth.
JPMorgan also emphasized the growing diversification strategies among biotech firms. Vertex Pharmaceuticals is expanding beyond its core business into renal disease treatments, while BioMarin continues strengthening its rare disease pipeline through acquisitions. Moderna is broadening the use of its mRNA technology into oncology despite ongoing financial concerns surrounding the company.
The report pointed to multiple upcoming clinical trial updates that could boost investor sentiment across the biotechnology market. Analysts expect major cardiovascular outcomes data related to Ionis-partnered therapies and important renal disease readouts from Vertex Pharmaceuticals to act as key catalysts over the next year.
JPMorgan assigned “Overweight” ratings to several biotech stocks, including Vertex Pharmaceuticals, Alnylam, BeOne Medicines, United Therapeutics, Insmed, Ascendis Pharma, Jazz Pharmaceuticals, Ionis, BioMarin, and Mirum Pharmaceuticals. Meanwhile, BioNTech, Incyte, and Halozyme received “Neutral” ratings. Moderna was rated “Underweight” due to concerns over financial risks despite progress in cancer research and mRNA development.
The bank also released updated price targets for December 2026. Vertex received a target of $515, Alnylam $420, BeOne Medicines $415, United Therapeutics $685, and Insmed $180. Moderna’s target was set at $40, while BioNTech received a $100 target.
JPMorgan believes the biotech sector is entering a period of durable expansion as companies scale beyond dependence on single products and continue building diversified, profitable healthcare franchises.
